Genetic Risk Analysis in Ovarian Cancer (GRACE) Administrative Supplement

卵巢癌遗传风险分析 (GRACE) 行政补充

基本信息

项目摘要

PROJECT SUMMARY/ABSTRACT An estimated 1 in 190 women carry a pathogenic variant in BRCA1/2, which is associated with an 46-57% risk of breast cancer and 20-40% risk of ovarian cancer by age 70. Carriers account for 10% and 15% of breast and ovarian cancer cases, respectively, and up to 20% of high-grade serous ovarian cancer cases, the most aggressive subtype. Despite recommendations that all ovarian cancer cases should receive genetic counseling and testing, irrespective of family history and age at onset, a recent national study indicated that only 10% of cases underwent genetic testing. This represents a missed opportunity to inform these women and their at-risk family members about their future cancer risk. The parent study of the proposed supplemental project aims to address this care gap by applying a traceback testing approach to retrospectively identify women who have a prior diagnosis of ovarian cancer. Individuals with a prior diagnosis of ovarian cancer who have not received genetic testing will be offered genetic counseling, testing, and cancer risk assessment. This study will leverage tumor registries to identify prior cases of ovarian cancer diagnosed within the past 24 years at two managed care healthcare systems (Kaiser Permanente Northwest and Kaiser Permanente Colorado). The use of archived pathology samples for germline genetic testing will allow family members of both living and deceased women to receive familial genetic cancer risk information. We will assess: 1) the feasibility of and barriers associated with using tumor registries and archived pathology samples for a traceback testing approach, and 2) explore the ethical, privacy, and policy implications associated with genetic testing in deceased patients to inform familial risk. This parent study will generate evidence on the feasibility of traceback testing using tumor registries and archived pathology samples which is critically important to guide future implementation of such programs beyond ovarian cancer. This supplemental project will build upon the aims of the parent study by using a bioethical research approach to characterize the impact of social determinants on receipt of genetic risk information at the index ovarian cancer diagnosis. The supplement will leverage the infrastructure of the parent study and will use the study population identified at Kaiser Permanente Northwest and Kaiser Permanente Colorado as well as an additional site, Kaiser Permanente Washington. A mixed methods approach will combine electronic medical record analysis through chart review and abstraction with qualitative analysis to capture care pathways to characterize the role of social determinants of health at specific points in these care pathways, such as referral and uptake. The results of this supplement will expand upon the findings of the parent study to inform future traceback studies by ensuring equitable access to genetic risk information for all patients with ovarian and other hereditary cancers.
项目总结/摘要 据估计,每190名妇女中就有1名携带BRCA 1/2的致病性变异,这与46-57%的风险相关。 70岁时患乳腺癌和卵巢癌的风险分别为20-40%。携带者占乳腺的10%和15% 和卵巢癌病例,分别高达20%和高级别浆液性卵巢癌病例,最 攻击亚型尽管建议所有卵巢癌病例都应接受遗传咨询, 和测试,无论家族史和发病年龄,最近的一项全国性研究表明,只有10%的 10例患者接受了基因检测。这意味着错过了向这些妇女及其高危群体提供信息的机会。 家庭成员的未来癌症风险。拟议补充项目的母研究旨在 通过采用追溯测试方法,追溯性地确定患有 卵巢癌的早期诊断既往诊断为卵巢癌且未接受过 基因检测将提供遗传咨询,检测和癌症风险评估。这项研究将利用 肿瘤登记,以确定在过去24年内诊断出的卵巢癌既往病例, 医疗保健系统(Kaiser Permanente Northwest和Kaiser Permanente科罗拉多)。使用 用于生殖系基因检测的存档病理学样本将允许在世和已故的家庭成员 妇女获得家族遗传癌症风险信息。我们将评估:1)可行性和障碍 与使用肿瘤登记和存档病理学样本进行追溯测试方法相关,以及 2)探索与已故患者基因检测相关的伦理、隐私和政策影响, 告知家族风险。这项母研究将为使用肿瘤进行追溯测试的可行性提供证据。 登记和存档病理学样本,这对于指导未来实施此类 卵巢癌以外的项目该补充项目将以母研究的目标为基础, 使用生物伦理学研究方法来描述社会决定因素对接受基因治疗的影响, 在指数卵巢癌诊断的风险信息。该补充将利用 母研究,并将使用Kaiser Permanente Northwest和Kaiser确定的研究人群 永久科罗拉多以及一个额外的网站,凯撒永久华盛顿。混合方法 一种联合收割机方法将通过图表审查和抽象的电子病历分析与定性 进行分析,以掌握护理途径,以确定健康的社会决定因素在特定阶段的作用, 这些护理途径,如转诊和吸收。本增刊的结果将在调查结果的基础上加以扩展 通过确保公平获取遗传风险信息,为未来的追溯研究提供信息 所有患有卵巢癌和其他遗传性癌症的患者。

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
An Examination of the Ethical and Legal Limits in Implementing "Traceback Testing" for Deceased Patients.
对已故患者实施“追溯测试”的道德和法律限制的检查。
  • DOI:
    10.1017/jme.2023.23
  • 发表时间:
    2022
  • 期刊:
  • 影响因子:
    2.1
  • 作者:
    Martucci, Jessica;Prado, Yolanda;Rope, Alan F.;Weinmann, Sheila;White, Larissa;Zepp, Jamilyn;Henrikson, Nora B.;Feigelson, Heather Spencer;Hunter, Jessica Ezzell;Lee, Sandra Soo-Jin
  • 通讯作者:
    Lee, Sandra Soo-Jin
Feasibility of a Traceback Approach for Using Pathology Specimens to Facilitate Genetic Testing in the Genetic Risk Analysis in Ovarian Cancer (GRACE) Study Protocol.
  • DOI:
    10.3390/jpm11111194
  • 发表时间:
    2021-11-13
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Kauffman TL;Prado YK;Reyes AA;Zepp JM;Sawyer J;White LL;Martucci J;Salas SB;Vertrees S;Rope AF;Weinmann S;Henrikson NB;Lee SS;Feigelson HS;Hunter JE
  • 通讯作者:
    Hunter JE
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jessica Ezzell Hunter其他文献

Premutation-Associated Disorders in Childhood and Adulthood
儿童期和成年期的前突变相关疾病
  • DOI:
    10.1007/978-3-319-33898-9_12
  • 发表时间:
    2016
  • 期刊:
  • 影响因子:
    5.8
  • 作者:
    R. Hagerman;A. Wheeler;Sarah E. Fitzpatrick;Jessica Ezzell Hunter
  • 通讯作者:
    Jessica Ezzell Hunter
Genomic sequencing in diverse and underserved pediatric populations: Parent perspectives on understanding, uncertainty, psychosocial impact, and personal utility of results
不同和服务不足的儿科人群中的基因组测序:父母对结果的理解、不确定性、社会心理影响和个人效用的观点
  • DOI:
    10.1016/j.gim.2025.101363
  • 发表时间:
    2025-04-01
  • 期刊:
  • 影响因子:
    6.200
  • 作者:
    Barbara B. Biesecker;Sara L. Ackerman;Kyle B. Brothers;Kelly M. East;Ann Katherine M. Foreman;Lucia A. Hindorff;Carol R. Horowitz;Gail P. Jarvik;Sara J. Knight;Michael C. Leo;Donald L. Patrick;Christine Rini;Jill O. Robinson;Nuriye Nalan Sahin-Hodoglugil;Anne Slavotinek;Sabrina A. Suckiel;David L. Veenstra;Randi E. Zinberg;Jessica Ezzell Hunter
  • 通讯作者:
    Jessica Ezzell Hunter

Jessica Ezzell Hunter的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jessica Ezzell Hunter', 18)}}的其他基金

Capturing and characterizing variability of cognition and behavior in Down syndrome
捕捉和表征唐氏综合症认知和行为的变异性
  • 批准号:
    10294846
  • 财政年份:
    2021
  • 资助金额:
    $ 16.41万
  • 项目类别:
Capturing and characterizing variability of cognition and behavior in Down syndrome
捕捉和表征唐氏综合症认知和行为的变异性
  • 批准号:
    10505106
  • 财政年份:
    2021
  • 资助金额:
    $ 16.41万
  • 项目类别:
Access to Genetic Information Leveraging Innovative Technology (AGILITY) Study
利用创新技术获取遗传信息(AGILITY)研究
  • 批准号:
    10492770
  • 财政年份:
    2021
  • 资助金额:
    $ 16.41万
  • 项目类别:
Leveraging tumor registries and pathology specimens to facilitate genetic testing and traceback for ovarian cancer
利用肿瘤登记和病理标本促进卵巢癌的基因检测和追溯
  • 批准号:
    10337328
  • 财政年份:
    2020
  • 资助金额:
    $ 16.41万
  • 项目类别:
Leveraging tumor registries and pathology specimens to facilitate genetic testing and traceback for ovarian cancer
利用肿瘤登记和病理标本促进卵巢癌的基因检测和追溯
  • 批准号:
    10579877
  • 财政年份:
    2020
  • 资助金额:
    $ 16.41万
  • 项目类别:

相似海外基金

A Longitudinal Qualitative Study of Fentanyl-Stimulant Polysubstance Use Among People Experiencing Homelessness (Administrative supplement)
无家可归者使用芬太尼兴奋剂多物质的纵向定性研究(行政补充)
  • 批准号:
    10841820
  • 财政年份:
    2023
  • 资助金额:
    $ 16.41万
  • 项目类别:
Proton-secreting epithelial cells as key modulators of epididymal mucosal immunity - Administrative Supplement
质子分泌上皮细胞作为附睾粘膜免疫的关键调节剂 - 行政补充
  • 批准号:
    10833895
  • 财政年份:
    2023
  • 资助金额:
    $ 16.41万
  • 项目类别:
Administrative Supplement: Life-Space and Activity Digital Markers for Detection of Cognitive Decline in Community-Dwelling Older Adults: The RAMS Study
行政补充:用于检测社区老年人认知衰退的生活空间和活动数字标记:RAMS 研究
  • 批准号:
    10844667
  • 财政年份:
    2023
  • 资助金额:
    $ 16.41万
  • 项目类别:
StrokeNet Administrative Supplement for the Funding Extension
StrokeNet 资助延期行政补充文件
  • 批准号:
    10850135
  • 财政年份:
    2023
  • 资助金额:
    $ 16.41万
  • 项目类别:
2023 NINDS Landis Mentorship Award - Administrative Supplement to NS121106 Control of Axon Initial Segment in Epilepsy
2023 年 NINDS 兰迪斯指导奖 - NS121106 癫痫轴突初始段控制的行政补充
  • 批准号:
    10896844
  • 财政年份:
    2023
  • 资助金额:
    $ 16.41万
  • 项目类别:
Biomarkers of Disease in Alcoholic Hepatitis Administrative Supplement
酒精性肝炎行政补充剂中疾病的生物标志物
  • 批准号:
    10840220
  • 财政年份:
    2023
  • 资助金额:
    $ 16.41万
  • 项目类别:
Administrative Supplement: Improving Inference of Genetic Architecture and Selection with African Genomes
行政补充:利用非洲基因组改进遗传结构的推断和选择
  • 批准号:
    10891050
  • 财政年份:
    2023
  • 资助金额:
    $ 16.41万
  • 项目类别:
Power-Up Study Administrative Supplement to Promote Diversity
促进多元化的 Power-Up 研究行政补充
  • 批准号:
    10711717
  • 财政年份:
    2023
  • 资助金额:
    $ 16.41万
  • 项目类别:
Administrative Supplement for Peer-Delivered and Technology-Assisted Integrated Illness Management and Recovery
同行交付和技术辅助的综合疾病管理和康复的行政补充
  • 批准号:
    10811292
  • 财政年份:
    2023
  • 资助金额:
    $ 16.41万
  • 项目类别:
Administrative Supplement: Genome Resources for Model Amphibians
行政补充:模型两栖动物基因组资源
  • 批准号:
    10806365
  • 财政年份:
    2023
  • 资助金额:
    $ 16.41万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了